- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13.11. | Orchestra BioMed Holdings, Inc. - 8-K, Current Report | - | SEC Filings | ||
| ORCHESTRA BIOMED Aktie jetzt für 0€ handeln | |||||
| 10.11. | Orchestra BioMed Holdings Q3 Loss Widens | 1 | RTTNews | ||
| 10.11. | Orchestra BioMed Holdings, Inc.: Orchestra BioMed Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates | 121 | GlobeNewswire (Europe) | Secured $147.6 million in proceeds and committed capital following completion of strategic transactions and concurrent public and private equity offerings, led by $71.6 million in committed capital... ► Artikel lesen | |
| 10.11. | Orchestra BioMed Holdings, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 03.11. | Orchestra BioMed files secondary offering of ~8M shares | 2 | Seeking Alpha | ||
| 28.10. | Orchestra BioMed, Terumo Sign $30 Million Strategic Agreements For Virtue SAB | 5 | RTTNews | ||
| 28.10. | Orchestra BioMed, Terumo terminate drug-eluting balloon distro deal in $30M agreement | 2 | MassDevice | ||
| 28.10. | Orchestra BioMed Holdings, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 27.10. | Orchestra BioMed enrolls first patient in Sirolumus AngioInfusion balloon trial | 1 | MassDevice | ||
| 27.10. | Orchestra BioMed Holdings, Inc.: Orchestra BioMed Announces First Patients Enrolled in Virtue SAB US Pivotal IDE Coronary Trial | 214 | GlobeNewswire (Europe) | Orchestra BioMed's Virtue® Sirolimus AngioInfusionTM Balloon ("Virtue SAB") is the first non-coated drug-eluting balloon system designed to deliver a large liquid dose of proprietary extended-release... ► Artikel lesen | |
| 09.10. | Orchestra BioMed Holdings, Inc.: Orchestra BioMed to Showcase Transformative Potential of AVIM Therapy in Keynote Presentation on Hypertensive Heart Disease at Georgia Innovation Summit | 2 | GlobeNewswire (USA) | ||
| 11.09. | Piper Sandler reiterates Overweight rating on Orchestra BioMed stock | 3 | Investing.com | ||
| 11.09. | Piper Sandler bestätigt "Overweight"-Rating für Orchestra BioMed | - | Investing.com Deutsch | ||
| 04.09. | Orchestra BioMed Holdings, Inc.: Orchestra BioMed Presents New AVIM Therapy Clinical Data at HRX Demonstrating Substantial and Sustained Blood Pressure Reductions that are Reproducible Upon Reactivation Following Washout | 2 | GlobeNewswire (USA) | ||
| 04.09. | Orchestra BioMed stock price target lowered to $10 at H.C. Wainwright | 1 | Investing.com | ||
| 26.08. | Orchestra BioMed reports positive data on blood pressure therapy | 1 | Investing.com | ||
| 26.08. | Orchestra BioMed meldet positive Studiendaten zu Blutdrucktherapie | 2 | Investing.com Deutsch | ||
| 26.08. | Orchestra BioMed Holdings, Inc.: Orchestra BioMed Announces Publication of Clinical Data Demonstrating Favorable Blood Pressure and Hemodynamic Effects of AVIM Therapy in JACC: Clinical Electrophysiology | 1 | GlobeNewswire (USA) | ||
| 20.08. | BTIG stuft Orchestra BioMed ab: Bedenken wegen Kapitalerhöhung und Zeitplanverzögerungen | 2 | Investing.com Deutsch | ||
| 20.08. | Orchestra BioMed stock rating downgraded to Neutral from Buy by BTIG | 1 | Investing.com |
1 2 3 Weiter >>
45 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 41,055 | +1,67 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Die Profitabilität dürfte 2026 zumindest stabil bleiben... ► Artikel lesen | |
| OLEMA PHARMACEUTICALS | 24,650 | +6,30 % | Biotech-Party! Olema-Aktie explodiert über 136 Prozent - die Hintergründe | Prämie dank Übernahme? Spektakuläre Studienergebnisse? Es ist keine Seltenheit, dass Biotech-Titel aus dem Stand an einem Tag prozentual dreistellig an Wert gewinnen können. Bei Olema Pharmaceuticals... ► Artikel lesen | |
| ARCELLX | 77,00 | -14,54 % | Arcellx stock initiated at Peerperform by Wolfe Research amid BCMA market competition | ||
| AVIDITY BIOSCIENCES | 71,02 | +0,65 % | Novartis CEO paid top dollar for Avidity to become a 'leader in neuromuscular diseases' | ||
| PRAXIS PRECISION MEDICINES | 172,51 | +1,61 % | Praxis Precision Medicines stock rating reiterated at Buy by TD Cowen | ||
| BEAM THERAPEUTICS | 23,705 | +6,76 % | Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease |
CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that... ► Artikel lesen | |
| BIONTECH | 84,75 | +2,11 % | Raus aus BioNTech? Rein in Evotec und Vidac Aktie? Was läuft da mit Johnson und Johnson? | Paukenschläge bei Biotechs: Partner Pfizer verkauft seine komplette Beteiligung am deutschen Biotech-Champion BioNTech. Sollten Anleger es genauso machen? Dagegen liefert Vidac Pharma mehr und mehr... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 30,780 | +4,48 % | Arcutis Biotherapeutics, Inc.: FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5 | Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026If approved, ZORYVE cream 0.3% would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in children... ► Artikel lesen | |
| COGENT BIOSCIENCES | 37,800 | +2,80 % | Will Cogent Biosciences' (COGT) Breakthrough Therapy Transform GIST Treatment? Analysts Think So | ||
| TANGO THERAPEUTICS | 10,515 | +4,84 % | Tango Therapeutics launches $100M at-the-market stock offering | ||
| QUANTERIX | 6,870 | +3,23 % | Quanterix Corp - 8-K, Current Report | ||
| ADMA BIOLOGICS | 18,105 | +5,45 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| DAY ONE BIOPHARMACEUTICALS | 9,020 | +5,99 % | Day One Biopharmaceuticals, Inc.: Day One to Acquire Mersana Therapeutics to Advance Mission to Bring New Medicines to People of All Ages with Life-Threatening Diseases | Acquisition expands Day One's portfolio with novel antibody-drug conjugate (ADC) emiltatug ledadotin (Emi-Le) Emi-Le has demonstrated early anti-tumor activity in an ongoing Phase 1 study for adenoid... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 17,390 | +7,41 % | Summit Therapeutics: Fortschritte bei Krebsstudien und solide Finanzlage auf Jefferies-Konferenz in London | ||
| RECURSION PHARMACEUTICALS | 4,235 | +1,56 % | Could Recursion Pharmaceuticals Be the Next Big Artificial Intelligence (AI) Stock? |
ORCHESTRA BIOMED HOLDINGS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +6,59 % bei einem Aktienkurs von 4,850 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ORCHESTRA BIOMED HOLDINGS INC finden Sie auf Wallstreet Online.